Cilostazol Tablet
Cilostazol is a phosphodiesterase III (PDE-3) inhibitor with antiplatelet, vasodilatory, and mild positive inotropic effects. In veterinary medicine, it is used off-label, primarily in dogs, for certain cardiovascular and thrombotic conditions.
The uses and pharmacology described below reflect the FDA-approved labeling for this active ingredient; your veterinarian determines whether and how they apply to your animal's treatment plan.
Veterinarians most commonly consider cilostazol for patients presented with certain cardiac arrhythmias, particularly those involving a slow heart rate (bradycardia) or when addressing peripheral arterial disease. It is frequently a point of discussion for managing cardiovascular health in patients where modulating vascular resistance and platelet activity is a clinical objective. By influencing intracellular signaling, your veterinarian can manage the physiological workload of the heart while simultaneously addressing the constriction of peripheral blood vessels.
At a pharmacological level, cilostazol acts by inhibiting the phosphodiesterase III enzyme, which leads to an increase in cyclic adenosine monophosphate (cAMP) within platelets and vascular smooth muscle cells. This increase in cAMP provides a mechanism for two primary actions: the inhibition of platelet aggregation and the relaxation of vascular smooth muscle, leading to vasodilation. In the heart muscle, this medication exhibits positive inotropic effects, which relates to the force of contraction and chronotropic effects, which relates to the heart rate. Your veterinarian will determine the clinical appropriateness of cilostazol based on diagnostic findings such as echocardiography, blood pressure monitoring and the specific hemodynamic profile of your pet.
Prescription only. Use only under the direction of a licensed veterinarian. This information is not a substitute for veterinary diagnosis, prescribing or monitoring. Compounded drugs are not approved by the FDA for safety or effectiveness.
Commonly observed effects following the administration of cilostazol include localized digestive changes such as vomiting, diarrhea or a temporary decrease in appetite. Because it influences heart rate and vascular tone, some animals may exhibit behavioral shifts including lethargy, restlessness or a noticeable increase in heart rate (tachycardia). Owners should monitor their pet for any unusual weakness or fainting episodes and contact their veterinarian promptly with any concerns regarding their pet’s response to the prescriptions.
This medication is typically used with extra caution or avoided in patients with known congestive heart failure of any severity, as phosphodiesterase III inhibitors have been associated with increased risks in certain heart failure categories. It is also carefully evaluated in pets with pre-existing bleeding disorders or severe renal and hepatic impairment. Significant interactions can occur if cilostazol is administered concurrently with other medications that inhibit certain liver enzymes or those that affect platelet function. Your veterinarian is the right person to provide guidance on the necessary monitoring frequency and the proper administration schedule to ensure the management approach remains suitable for your pet's cardiac needs.
Yes. Cilostazol is a prescription medication and can only be dispensed by a licensed pharmacy upon receipt of a valid authorization from a licensed veterinarian. Mixlab verifies all veterinarian-client-patient relationships before any medication is prepared or shipped to your home.
Yes. While cilostazol is available in commercial tablet formats intended for human use, Mixlab specializes in compounding the active ingredient into customized strengths and flavored dosage forms—such as flavored oral liquids or smaller capsules—to suit the specific needs of dogs. The decision between a commercial and compounded product rests with the prescribing veterinarian.
Veterinarians may select cilostazol because its mechanism of action includes a positive chronotropic effect, which relates to increasing the heart rate. By acting on the signaling pathways that control the heart's electrical activity, it provides a method for managing certain types of bradycardia.
The most important observational signs to monitor include a very fast heartbeat, persistent vomiting or unusual tiredness. If your pet appears to have trouble breathing or experiences a sudden collapse, you should contact your veterinarian immediately for a clinical assessment and potential diagnostic review.
